Mebendazole, an anthelmintic drug used to treat parasitic worm infections such as ascariasis, enterobiasis, and trichuriasis. Mebendazole is a synthetic benzimidazole compound developed by Janssen Pharmaceutica in Belgium and introduced in the early 1970s. Approved by the FDA in 1971, it became a widely used broad-spectrum anthelmintic for treating parasitic infections. The drug marked a major advance in managing intestinal worms by disrupting the parasites’ microtubule structures. Its history is marked by its broad effectiveness against intestinal helminths by inhibiting microtubule synthesis in parasites, leading to impaired glucose uptake and eventual parasite death. Mebendazole, a benzimidazole class anthelmintic, became widely used as a first-line treatment for soil-transmitted helminth infections and is included in many public health deworming programs globally. Its development and use were supported by large-scale community treatment initiatives and essential medicine listings, which helped expand access in endemic regions.
BRAND NAMES
Emverm
Ovex
Vermacar
MECHANISM OF ACTION
Mebendazole is a benzimidazole anthelmintic that acts by binding selectively to parasite β-tubulin, thereby inhibiting microtubule polymerization in intestinal helminths. This disruption of microtubule formation impairs essential cellular processes such as glucose uptake and intracellular transport, leading to depletion of glycogen stores and reduced ATP production.
PHARMACOKINETICS
Absorption
Mebendazole is poorly absorbed from the gastrointestinal tract, with bioavailability typically less than 10% after oral administration. The presence of fatty food can increase its absorption slightly by enhancing its solubility.
Distribution
The drug is highly protein-bound (about 90–95%), which influences its distribution profile. Limited penetration into most tissues occurs, but it can reach sites of parasitic infection outside the gut when absorption is increased or with prolonged dosing.
Metabolism
Mebendazole is extensively metabolized in the liver after absorption. The primary metabolic pathway involves hepatic biotransformation via the cytochrome P450 system, mainly CYP3A4, leading to inactive metabolites such as amino and hydroxy derivatives.
Elimination
Mebendazole and its metabolites are eliminated primarily through the bile into the feces, which accounts for the major route of excretion. Only a small fraction is excreted in the urine, mostly as inactive metabolites.
PHARMACODYNAMICS
Mebendazole exerts its anthelmintic effect by selectively binding to β-tubulin of parasitic worms, inhibiting microtubule assembly. This disrupts essential cellular functions such as glucose uptake, intracellular transport, and mitotic spindle formation. The immobilized worms eventually die and are expelled from the gastrointestinal tract. Mebendazole acts primarily on intestinal helminths due to its poor systemic absorption, making it highly effective in luminal infections with minimal effect on human cells.
ADMINISTRATION
Mebendazole is administered orally in tablet or chewable tablet form. It can be taken with or without food, although taking it with a fatty meal may slightly enhance absorption. For most intestinal worm infections, a single dose or short course (usually 1–3 days) is sufficient, depending on the type of parasite.
DOSAGE AND STRENGTH
Mebendazole is available mainly as 100 mg chewable tablets and sometimes as a 500 mg single-dose tablet. The dosage varies depending on the type of intestinal worm infection being treated. For enterobiasis (pinworm infection), a single 100 mg dose is usually given and may be repeated after two weeks if reinfection occurs. For ascariasis, trichuriasis, and hookworm infections, the common regimen is 100 mg twice daily for three days or a single 500 mg dose in some cases.
DRUG INTERACTIONS
Mebendazole may interact with drugs that affect hepatic enzyme activity, particularly CYP450 inducers such as carbamazepine and phenytoin, which can reduce its plasma concentration and therapeutic effectiveness. Conversely, cimetidine may increase mebendazole levels by inhibiting its metabolism, potentially enhancing both efficacy and risk of adverse effects.
FOOD INTERACTIONS
Food has a limited but notable effect on the absorption of mebendazole. Taking the drug with a fatty meal can increase its absorption from the gastrointestinal tract, leading to slightly higher systemic exposure, although its primary action remains within the intestine.
CONTRAINDICATIONS
Mebendazole is contraindicated in individuals with known hypersensitivity to mebendazole or other benzimidazole derivatives. It should be avoided in pregnancy, particularly during the first trimester, unless the potential benefit clearly outweighs the risk to the fetus.
SIDE EFFECTS
Abdominal pain or discomfort
Diarrhea
Nausea and vomiting
Flatulence (gas formation)
Headache
Dizziness
Rash or mild skin reactions.
OVER DOSE
Mebendazole overdose is uncommon but may lead to exaggerated gastrointestinal and systemic effects. Symptoms can include nausea, vomiting, abdominal cramps, diarrhea, and dizziness. With very high or prolonged excessive doses, more serious effects such as hepatotoxicity, reversible liver enzyme elevation, neutropenia, or bone marrow suppression may occur.
TOXICITY
Mebendazole toxicity is uncommon due to its poor systemic absorption, but it may occur with high doses or prolonged therapy. Toxic effects primarily involve the liver and blood system, including elevated liver enzymes, hepatitis, and, in rare cases, hepatotoxicity.
